Day: October 25, 2019

RICHMOND HILL, Ontario, Oct. 25, 2019 (GLOBE NEWSWIRE) — Helix BioPharma Corp. (TSX: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2019.FINANCIAL REVIEWThe Company recorded a net loss and total comprehensive loss of $7,526,000 and $8,625,000 (a loss per common share of $0.07 and $0.09) for the fiscal years ended July 31, 2019 and 2018 respectively. Research and developmentResearch and development expenses totalled $6,084,000 and $6,524,000, respectively for the twelve-month periods ended July 31, 2018 and 2017.The following table outlines research and development costs expensed and investment tax credits for the Company’s significant research and development projects for the fiscal years ended July 31:L-DOS47...

MANITOWOC, Wis., Oct. 25, 2019 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of turnkey enterprise-grade LED lighting solutions, controls and integrated IoT capabilities, today announced that it will host a conference call to review its fiscal 2020 second quarter results and business trends on Wednesday, November 6, 2019, at 10:00 a.m. Eastern Time. Orion CEO, Mike Altschaefl, and CFO, Bill Hull, will host the investor call. Orion plans to release its results premarket the same day.About Orion Energy SystemsOrion is a provider of turnkey enterprise-grade LED lighting solutions, controls and integrated IoT capabilities designed to reduce energy consumption and enhance business performance and efficiency. Orion designs, manufactures, markets and manages the installation and maintenance of...

LEI-kode: 213800BGF1TQB5M6PH65Selskabsmeddelelse nr. 13/2019Møns Bank opjusterer forventningerne til resultatet for 2019. Bankens resultat før skat per Q3 2019 forventes at lande mellem 29-30 mio. kr., og resultatet er således tæt på nederste grænse for tidligere udmeldte forventninger for hele året. Møns Bank opjusterer derfor forventningerne til resultatet før skat for hele 2019 fra 30-35 mio. kr. til mellem 34-40 mio. kr.Opjusteringen er begrundet i udviklingen i bankens basisdriften, der per Q3 2019, forventes at lande på mellem 28-29 mio. kr. Bankens basisdrift opjusteres derfor samtidig med 5 mio. kr. fra et niveau på 30-35 mio. kr. til mellem 35–40 mio. kr. for hele 2019. Den positive udvikling og opjusteringen er båret af et generelt højt aktivitetsniveau i banken, hvor aktiviteten med formidling af realkreditlån, herunder mange...

OUTOTEC OYJ   STOCK EXCHANGE RELEASE   OCTOBER 25, 2019  at 2:30 PMThe Finnish Financial Supervisory Authority has approved a supplement to the prospectus prepared for the combination of Outotec and the Metso Minerals BusinessThe Finnish Financial Supervisory Authority has today on October 25, 2019, approved a supplement to the Finnish language demerger prospectus (the “Prospectus”) relating to the combination of Outotec Oyj (“Outotec”) and Metso Corporation’s (“Metso”) Minerals business (the “Metso Minerals Business”).The supplement relates to Outotec’s interim report as at and for the nine months ended September 30, 2019, and the Metso Minerals Business’ selected illustrative financial information as at and for the nine months ended September 30, 2019, both of which were published on October 25, 2019.The supplement, together with the...

OUTOTEC OYJ   PÖRSSITIEDOTE   25.10.2019  KLO 14.30Finanssivalvonta on hyväksynyt Outotecin ja Metso Minerals -liiketoiminnan yhdistymistä varten laaditun esitteen täydennyksenFinanssivalvonta on tänään 25.10.2019 hyväksynyt Outotec Oyj:n (”Outotec”) ja Metso Oyj:n (”Metso”) Minerals -liiketoiminnan (”Metso Minerals -liiketoiminta”) yhdistymistä koskevan suomenkielisen jakautumis- ja listalleottoesitteen (”Esite”) täydennyksen.Täydennys liittyy 25.10.2019 julkistettuihin Outotecin osavuosikatsaukseen 30.9.2019 päättyneeltä yhdeksän kuukauden jaksolta ja Metso Minerals -liiketoiminnan valikoituihin havainnollistaviin taloudellisiin tietoihin 30.9.2019 päättyneeltä yhdeksän kuukauden jaksolta.Täydennys on saatavilla yhdessä Esitteen kanssa 25.10.2019 alkaen internetissä osoitteissa www.outotec.fi/landing-pages/metso-outotec ja www.metso.com/fi/metso-outotec-neles...

PARSIPPANY, N.J., Oct. 25, 2019 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results before the open of the U.S. markets on Thursday, November 7, 2019. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.To participate in the conference call, dial 1-877-845-0779 and provide the passcode 8077145. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com.For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode...

NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) — Acreage Holdings, Inc. (“Acreage Holdings” or “Acreage”) (CSE: ACRG.U) (OTCQX: ACRGF) (FSE: 0VZ) and GreenAcreage Real Estate Corp. (“GreenAcreage”), an independent real estate investment trust, today announced the closing of a series of sale-and-leaseback transactions for the sale of certain properties and facilities from Acreage Holdings to GreenAcreage for an aggregate of approximately $18 million to Acreage Holdings and approximately $23 million overall including payments to a third-party seller.  The locations funded and closed today include facilities in Massachusetts, Florida and Pennsylvania.  Acreage Holdings and GreenAcreage expect to close on additional facilities in Illinois and Connecticut within the next thirty days.Acreage Holdings is expected to undertake significant expansion...

GREENWICH, Conn., Oct. 25, 2019 (GLOBE NEWSWIRE) — XPO Logistics, Inc. (NYSE: XPO), a leading global provider of transportation and logistics solutions, and Susan G. Komen®, a leading nonprofit breast cancer organization, today announced a national partnership in the fight to end breast cancer.To raise awareness of Komen’s mission, XPO has added Komen’s iconic pink running ribbon logo to company trucks. XPO unveiled the truck design on October 25, one day before the 2019 Komen Dallas Race for the Cure. Each year, XPO employees join nearly 850,000 people worldwide in participating in Race for the Cure events.Bradley Jacobs, chairman and chief executive officer of XPO Logistics, said, “We’re proud to partner with Susan G. Komen in supporting a cause close to our employees’ hearts. XPO is committed to helping women everywhere lead...

$4.2 million net income, or $10.6 million net income, as adjusted$0.02 diluted EPS for the quarter, $0.06 as adjustedDeclares $0.03 quarterly dividendNEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) — WisdomTree Investments, Inc. (NASDAQ: WETF), an exchange-traded fund (“ETF”) and exchange-traded product (“ETP”) sponsor and asset manager today reported net income of $4.2 million or $0.02 diluted EPS in the third quarter.  Adjusted net income (a non-GAAP measure1) was $10.6 million1 or $0.06 diluted EPS1.  This compares to net income of $22.0 million or $0.13 diluted EPS (as adjusted, $14.8 million1 or $0.09 diluted EPS1) in the third quarter of last year and net income of $2.5 million or $0.01 diluted EPS (as adjusted, $7.8 million1 or $0.05 diluted EPS1) in the second quarter of 2019.  WisdomTree CEO Jonathan Steinberg said, “Our continued...

Global NuTide:121 Study will Enroll up to 828 Patients and Compare Acelarin plus Cisplatin to Gemcitabine plus CisplatinPrimary Endpoints of Overall Survival and Objective Response RateThree Interim Analyses, Including Two Designed to Support Accelerated ApprovalEDINBURGH, United Kingdom, Oct. 25, 2019 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) announced that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for its Phase III study (NuTide:121) of the investigational drug Acelarin in combination with cisplatin for patients with previously untreated locally advanced or metastatic biliary tract cancer.“We are pleased to have received clearance of our IND from the FDA,” said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer.  “We are also excited by NuTide:121’s potential,...